DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’

Coverage from The Daily Beast, Yahoo, E! News, People.com, and Entertainment Weekly reports that Grammy-winning producer and artist DJ Khaled has disclosed a substantial weight-loss transformation after reaching a peak weight of approximately 300 pounds. The outlets variously cite a loss of 75 pounds (Yahoo, E! News, People.com) or up to 90 pounds (Entertainment Weekly, The Daily Beast), attributing the change to the GLP-1 receptor agonist Wegovy combined with diet and exercise adjustments. DJ Khaled is quoted across the coverage stating he "needed help" and "needed a little help" to achieve the results, framing the medication as a tool rather than a sole solution. The reports note his motivation centers on family health and longevity, with People.com highlighting an exclusive angle on his transformation for his family.

The coverage emphasizes the celebrity disclosure of prescription weight-loss medication use, a topic that has drawn increasing public attention in entertainment and health circles. Outlets frame the story around transparency, with DJ Khaled's candid remarks about needing pharmaceutical assistance presented as notable in a landscape where such admissions are not always made. Entertainment Weekly's headline mirrors the trend label exactly, while The Daily Beast focuses on the "drastic" visual debut. Yahoo and E! News lead with the 75-pound figure and the Wegovy brand name. People.com positions the narrative as an exclusive family-oriented journey.

Contextually, the reports arrive amid broader cultural conversation about GLP-1 agonists such as semaglutide (marketed as Wegovy, Ozempic) and their rapid adoption beyond diabetes treatment into weight management. Celebrity disclosures have accelerated public awareness and debate over access, cost, side effects, and societal pressure. DJ Khaled's platform as a music mogul, social-media personality, and father amplifies reach beyond typical health-reporting audiences. The coverage does not specify when he began treatment, clinical details, or whether he continues the medication. It also does not address insurance, cost, or medical supervision beyond his general attribution of the drug as a factor. The 300-pound peak weight and the 75-to-90-pound range are the only quantitative anchors provided across the five sources.

What to watch next includes whether DJ Khaled expands on the regimen in interviews, social media, or a dedicated platform; whether medical professionals or advocacy groups respond to the high-profile endorsement; and whether the disclosure influences public perception or prescription trends for Wegovy. The coverage does not indicate upcoming appearances, partnership announcements, or clinical data releases tied to the story. Continued monitoring of entertainment and health-media outlets will clarify if this becomes a sustained narrative or a single-cycle celebrity health reveal.